The Macula in Your Eyes: Function, Problems, and Health

The macula is a small, pigmented patch near the center of your retina, and it is responsible for nearly everything you think of as “seeing.” Reading, recognizing faces, driving, judging color and fine detail all depend on this region, which spans only about five millimeters across. When the macula is healthy, you probably never think about it. When it degenerates or swells, central vision can blur or disappear while your peripheral sight stays intact, a disorienting experience that makes the macula’s outsized role suddenly obvious.

How the Macula Produces Sharp Vision

Your retina lines the inside back wall of the eye and contains millions of light-sensitive cells. Most of the retina handles peripheral vision in relatively coarse resolution. The macula is different. Its center, called the fovea, is a shallow pit where the inner layers of retinal tissue are pushed aside so light can hit the photoreceptors with as little interference as possible. That thinning of overlying tissue improves image quality at the point where you aim your gaze.

The photoreceptors packed into the fovea are almost exclusively cones, the cells that detect color and fine detail. These foveal cones are unusually elongated and narrow compared with cones elsewhere in the retina, which lets them crowd together more tightly and sample incoming light at a higher rate.

¹ The fovea is also unique to primates among mammals. It undergoes significant structural changes during postnatal development, and the displacement of inner retinal layers increases the transparency of the central tissue, sharpening the image the cones receive.²

Surrounding the fovea, the macula also harbors a distinctive yellow pigment made up of two carotenoids, lutein and zeaxanthin. This macular pigment acts as a built-in blue-light filter and also has antioxidant and anti-inflammatory properties.³ Lab studies have shown that lutein in particular is effective at absorbing blue light, outperforming zeaxanthin and other carotenoids in filter tests.⁴ Because high-energy blue wavelengths can damage photoreceptors over time, macular pigment is thought to serve a protective role, one that becomes clinically relevant when its density is low.

Beneath the photoreceptors sits the retinal pigment epithelium, or RPE, a single layer of cells that recycles visual pigments, removes waste products, and passes nutrients from the blood supply in the choroid below. Blood reaches the outer retina through tiny choroidal vessels, not through retinal arteries. In fact, the center of the fovea has no retinal blood vessels at all, a feature called the foveal avascular zone, which further reduces anything that might scatter light before it reaches the cones. The choroidal blood supply, however, can undergo age-related changes that contribute to diseases such as age-related macular degeneration.⁵

Age-Related Macular Degeneration

Age-related macular degeneration, commonly called AMD, is the leading cause of irreversible vision loss in people over 65 in Western countries.⁶ AMD exists on a spectrum. In early AMD, small yellow deposits called drusen accumulate under the retina, and subtle changes in visual function may begin even before you notice symptoms. Late AMD splits into two forms that behave very differently.

In wet (neovascular) AMD, abnormal new blood vessels grow from the choroid into or under the retina. These vessels are fragile and leak fluid and blood, which can rapidly damage the macula and cause sudden, severe central vision loss.⁷ Wet AMD often progresses over weeks or months rather than years, making it the more immediately threatening form.

Dry (atrophic) AMD is more gradual. Its advanced stage, called geographic atrophy, involves the slow death of RPE cells, photoreceptors, and the underlying choroidal capillaries. Researchers have linked the progression of geographic atrophy to chronic overactivation of the complement system, a branch of the immune system that normally helps clear infections and debris but in this case turns destructive.⁸ Genetic studies have confirmed that mutations in complement genes are a major source of AMD risk.⁹ Understanding this immune-system involvement has reshaped treatment research, as discussed later.

Other Conditions That Target the Macula

AMD is the most talked-about macular disease, but several other conditions can disrupt this tissue.

Diabetic Macular Edema

Diabetic macular edema, or DME, is the most common cause of vision loss in people with diabetes. Chronically high blood sugar damages the tiny blood vessels throughout the retina, and when those vessels leak fluid into the macula, it swells and vision blurs.¹⁰ DME can occur at any stage of diabetic retinopathy. Because the condition develops gradually, some people do not realize their central vision is worsening until significant damage has occurred, which is one reason regular eye exams matter for anyone with diabetes.

Stargardt Disease

Stargardt disease is the most common inherited macular dystrophy. It follows an autosomal recessive inheritance pattern, meaning a person needs to carry two copies of a faulty gene, typically ABCA4, for the disease to appear. Photoreceptors in the central retina degenerate, causing progressive vision loss that often begins in childhood or adolescence. Severity varies widely depending on the specific mutations involved, ranging from severe childhood-onset to milder late-onset forms driven by particular gene variants.¹¹ There is currently no approved treatment for Stargardt disease, though gene therapy trials are underway.

Macular Holes and Vitreomacular Traction

The vitreous, the gel that fills the center of your eye, is normally attached to the retina. As you age, the vitreous shrinks and pulls away in a process called posterior vitreous detachment. Usually this separation goes smoothly, but sometimes the vitreous stays stuck to the macula and tugs on it. That abnormal adhesion can pull on the fovea, causing distorted vision, swelling, or even a full-thickness macular hole.¹² Vitreomacular traction can also lead to cyst-like pockets of fluid in the macula and small detachments of the foveal retina.¹³ Treatment options range from watchful waiting to surgical vitrectomy, depending on how much traction exists and how much vision is affected.

Epiretinal Membranes

An epiretinal membrane is a thin sheet of scar-like tissue that grows across the surface of the macula. It can contract and pucker the retina beneath it, causing wavy or distorted vision, a symptom called metamorphopsia. Imaging with adaptive optics has revealed that this distortion is linked to tiny folds, called microfolds, in the foveal photoreceptor layer itself.¹⁴ Mild epiretinal membranes may need no treatment, but when distortion interferes with daily life, surgery to peel the membrane off the retina can improve vision.

Central Serous Chorioretinopathy

Central serous chorioretinopathy, or CSCR, tends to affect younger adults, particularly men in their 30s and 40s who are under significant stress. Fluid leaks from the choroid and collects under the macula, causing a bubble-like detachment that distorts or dims central vision. The link to stress is well documented. Studies have found that people with CSCR have higher cortisol levels than matched controls, and stress scores strongly correlate with cortisol and homocysteine levels in these patients.¹⁵ Elevated sympathetic activity and glucocorticoid levels are thought to alter choroidal blood flow and increase vessel permeability.¹⁶ Most episodes resolve on their own within a few months, but chronic or recurrent CSCR can lead to lasting damage.

How Macular Problems Are Detected

A standard eye exam with a dilated fundus check can reveal drusen, hemorrhages, and obvious swelling, but the tool that transformed macular diagnosis is optical coherence tomography, or OCT. OCT uses light waves to create detailed cross-sectional images of the retina, producing scans with resolution fine enough to show individual retinal layers. It is quick, painless, and does not require any dye injection.¹⁷

Since its introduction in the 1990s, OCT has become indispensable for diagnosing and monitoring virtually every macular condition.¹⁸ Your retina specialist can measure exact fluid levels in DME, track the growth of geographic atrophy, map the contours of a macular hole, or assess how much an epiretinal membrane is distorting the fovea. Newer OCT angiography variants add blood-flow information without injecting contrast dye, which helps detect the abnormal vessels in wet AMD early. If you are being monitored for any macular condition, you have almost certainly had OCT scans and will continue to get them at each visit to track how the disease is responding to treatment.

Treatments for Wet AMD

Before about 2005, wet AMD usually meant relentless vision loss. The arrival of anti-VEGF therapy changed the prognosis dramatically. VEGF, or vascular endothelial growth factor, is a protein that promotes the growth of new blood vessels. In wet AMD, too much VEGF drives the formation of leaky, fragile vessels under the macula. Drugs that block VEGF, injected directly into the eye, can shrink those vessels and dry up fluid. Visual acuity can actually improve with treatment, though sustaining that improvement usually requires repeated injections over months or years.¹⁹

The most commonly used anti-VEGF agents include ranibizumab, aflibercept, and bevacizumab. Newer formulations aim to last longer in the eye so patients can go longer between injections, a genuine quality-of-life concern given that some people need injections every month or two. While anti-VEGF therapy works well for many patients, some eyes respond poorly, and there has been research interest in VEGF-independent pathways. Animal studies have shown that blocking the mineralocorticoid receptor pathway, for instance, can inhibit abnormal vessel growth through a different mechanism altogether.²⁰ Whether approaches like this will translate into human therapies remains to be seen, but the field is actively searching for alternatives to supplement or extend anti-VEGF treatment.

Treatments for Geographic Atrophy

For decades, dry AMD with geographic atrophy had no approved therapy. That changed in 2023 when the FDA approved two complement inhibitors: pegcetacoplan and avacincaptad pegol. Both target the complement cascade that fuels the immune-mediated destruction of RPE and photoreceptors, but they work at different points. Pegcetacoplan binds to C3 and C3b, proteins near the top of the cascade where all three complement activation pathways converge.²¹ Avacincaptad pegol targets C5, a downstream complement factor.²²

These drugs slow the expansion of atrophic patches but do not restore lost tissue. Expectations need to be realistic: the goal is to preserve what vision remains, not to bring back what has already been lost. Both are given by intravitreal injection, and researchers are still working out the long-term safety profile, including a small observed risk of developing wet AMD after starting complement inhibitor treatment. Still, the fact that there is any pharmacological option for geographic atrophy marks a significant shift after years of having nothing to offer patients with this form of the disease.²³

Stem Cell Therapy and the Horizon Ahead

Because geographic atrophy involves the death of RPE cells, one logical idea is to replace them. Over the past decade, multiple clinical trials have explored transplanting RPE cells grown from stem cells, both from induced pluripotent stem cells and from human embryonic stem cells. Preliminary results have shown safety and hints of potential benefit, though real-world challenges remain around cell survival, integration with the existing retina, and immune rejection.²⁴

A newer approach uses adult RPE stem cells rather than embryonic or reprogrammed cells. A first-in-human trial of a product called RPESC-RPE-4W, derived from adult RPE stem cells, has completed its initial low-dose cohort and reported consistent safety in preclinical work.²⁵ This is still very early-stage work, and it will take years of larger trials before anyone knows whether stem cell transplants can meaningfully restore macular function. But for a disease where the endpoint used to be simply watching vision deteriorate, the pipeline of experimental treatments is encouraging.

Diet, Supplements, and Smoking

Lutein and zeaxanthin, the carotenoids that form the macula’s yellow pigment, are entirely dietary in origin. Your body cannot synthesize them; they come from food, particularly dark leafy greens, eggs, and brightly colored fruits and vegetables. Serum levels, dietary intake, and retinal concentrations of these carotenoids tend to correlate, though many variables including digestion, absorption, and transport influence how much actually reaches your macula.²⁶

The landmark AREDS and AREDS2 clinical trials tested whether supplements could slow AMD progression. The original AREDS formula contained antioxidant vitamins C and E, zinc, and beta-carotene. AREDS2 swapped in lutein and zeaxanthin for beta-carotene, partly because beta-carotene raised lung cancer risk in smokers. The initial five-year AREDS2 results did not show a statistically significant reduction in progression to advanced AMD from lutein and zeaxanthin alone.²⁷ But ten-year follow-up data told a more favorable story: participants assigned to lutein and zeaxanthin had a roughly 9% lower hazard of progressing to late AMD, and when directly compared head-to-head against beta-carotene, lutein and zeaxanthin showed a 15% lower hazard of progression.²⁸ Omega-3 fatty acids, also tested in AREDS2, did not reduce progression. Lowering the zinc dose from the original formulation also made no difference. The practical takeaway is that the current AREDS2 formula, with lutein and zeaxanthin replacing beta-carotene, is the recommended supplement for people at intermediate or high risk of advanced AMD.

Smoking is the single most modifiable risk factor for AMD. A large Australian cohort study found that current smokers had about a four-fold higher risk of late AMD compared with people who had never smoked. Even former smokers carried an elevated risk, roughly three times higher for geographic atrophy specifically. The risk climbed further when smoking combined with low HDL cholesterol or low fish consumption.²⁹ If there is a single piece of advice that comes out of the AMD literature with the most force, it is to not smoke or to quit if you currently do.

When to See an Eye Doctor

Many macular conditions, especially AMD and DME, develop slowly enough that you may not notice early changes on your own. A simple at-home check involves looking at an Amsler grid, a square of evenly spaced horizontal and vertical lines with a central dot. If any of the lines appear wavy, broken, or missing when you cover one eye and focus on the center, that is worth reporting to an eye doctor. Sudden onset of wavy lines or a dark spot in your central vision is more urgent, because wet AMD and macular holes can progress quickly.

Guidelines vary by country, but most recommend dilated eye exams starting at age 40 for people without risk factors, and more frequently for anyone with a family history of AMD, diabetes, high myopia, or prior retinal disease. OCT screening is not universally recommended for everyone, but it is standard for monitoring once a macular condition has been identified. Given that treatments for both wet AMD and geographic atrophy work best when started before too much tissue is lost, catching changes early genuinely alters the outcome. The inconvenience of regular eye exams is a small price for preserving the few millimeters of tissue that your central vision depends on.